NCT01072149View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 1, 2010

Primary Completion Date

July 1, 2010

Study Completion Date

July 1, 2010

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Fluticasone Furoate (FF)/GW642444 Inhalation Powder

Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

DEVICE

placebo

placebo

Trial Locations (8)

29118

GSK Investigational Site, Orangeburg

29303

GSK Investigational Site, Spartanburg

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

32720

GSK Investigational Site, DeLand

32822

GSK Investigational Site, Orlando

42431

GSK Investigational Site, Madisonville

43215

GSK Investigational Site, Columbus

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01072149 - A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo | Biotech Hunter | Biotech Hunter